Oorja Bio, Incorporated

Oorja Bio, Inc. is a Houston-based biopharmaceutical company specializing in innovative therapies for cardiopulmonary and fibrotic disorders, focusing on addressing the underlying causes of these diseases. Founded in 2023, Oorja Bio, Inc. operates in the biopharmaceutical industry and is dedicated to developing treatments for serious fibrotic diseases.

The company is located in Houston, US and focuses primarily on clinical-stage drug development. The company raised USD 30. 00 mn in Series A funding led by Westlake Village BioPartners, marking an important step in its growth trajectory and enabling further advancement of its flagship product ORJ-001. Oorja Bio, Inc.

has engaged in one deal as of 2026-05-20, which signifies its early-stage development and investor interest in its therapeutic offerings. Oorja Bio specializes in developing innovative therapies specifically targeting cardiopulmonary and fibrotic disorders. Their core product, ORJ-001, is a first-in-class peptide therapeutic designed for subcutaneous administration aimed at treating idiopathic pulmonary fibrosis (IPF). ORJ-001 works by restoring the function of alveolar epithelial type 2 (AEC2) cells, promoting alveolar repair and reducing the inflammatory and fibrotic signaling associated with pulmonary fibrosis.

This product is part of Oorja's clinical-stage pipeline and is aimed at patients in the United States and Europe suffering from serious fibrotic diseases. Oorja Bio operates primarily within a clinical development framework, focusing on partnerships and collaborations within the biopharmaceutical sector to generate revenue. The company engages in direct-to-consumer transactions for its therapies, leveraging clinical trial data to attract investors and potential partners. Their revenue structure includes milestone payments and royalties related to the development and commercialization of ORJ-001, though specific pricing plans for their products are not disclosed.

In May 2026, Oorja Bio, Inc. raised USD 30 mn in Series A funding, which will be utilized to advance ORJ-001 and expand their therapeutic pipeline. The company plans to launch additional products addressing fibrotic diseases and aims to penetrate new markets in both the United States and Europe. This funding will support their initiatives to enhance product development and strengthen market presence.